Ivantis Revenue and Competitors
Estimated Revenue & Valuation
- Ivantis's estimated annual revenue is currently $19.3M per year.
- Ivantis received $25.0M in venture funding in January 2017.
- Ivantis's estimated revenue per employee is $251,000
- Ivantis's total funding is $132.4M.
Employee Data
- Ivantis has 77 Employees.
- Ivantis grew their employee count by -8% last year.
Ivantis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CSO | Reveal Email/Phone |
2 | VP, Finance | Reveal Email/Phone |
3 | Sr. Director, Clinical Operations | Reveal Email/Phone |
4 | Global Director Training and Market Development | Reveal Email/Phone |
5 | Chief Operating Officer & Chief Compliance Officer | Reveal Email/Phone |
6 | Sr. Director Global Training | Reveal Email/Phone |
7 | Manager, Manufacturing and Facilities Engineering | Reveal Email/Phone |
8 | Regional Business Manager | Reveal Email/Phone |
9 | Senior Manager Marketing | Reveal Email/Phone |
10 | CEO/President/Chairman | Reveal Email/Phone |
Ivantis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Ivantis?
Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$132.4M
Total Funding
77
Number of Employees
$19.3M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Ivantis News
Key Players Glaukos Corporation, Ivantis, Allergan, Ellex The New York Irish Emgirant...
... Equinox, Ivantis, Sight Sciences, TearClear, ViaLase ... Elios Vision, Ellex, Glaukos, iSTAR, Ivantis, New World Medical, Nicox,...
IRVINE, Calif., Sept. 15, 2021 /PRNewswire/ -- Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corpo ...
IRVINE, Calif., Nov. 17, 2020 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has desig ...
There are four FDA-approved MIGS stents: the Glaukos's iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22.3M | 77 | 10% | N/A |
#2 | $20.8M | 77 | 22% | N/A |
#3 | $22.3M | 77 | -1% | N/A |
#4 | $15.8M | 77 | -3% | N/A |
#5 | $19.3M | 77 | -13% | $1.6B |
Ivantis Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-02-04 | $27.0M | B | Ascension Health Ventures | Article |
| 2013-08-21 | $5.0M | B | EDBI of Singapore | Article |
| 2014-01-14 | $46.5M | B | Multiple | Article |
| 2014-09-24 | $25.0M | B | Foresite Capital | Article |
| 2017-01-10 | $25.0M | C | RA Capital Management | Article |